Liposomal Amphotericin B (AmBisome) Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ASPEN)
Status:
Completed
Trial end date:
2018-11-03
Target enrollment:
Participant gender:
Summary
Dosing guidelines for liposomal amphotericin B (AmBisome) in (morbidly) obese patients are
not available. Subsequently, the pharmacokinetic profile of AmBisome in this specific patient
population is still largely unknown.
To build a valid pharmacokinetic model, obese patients with a BMI ≥ 40 undergoing endoscopic
gastric bypass surgery will receive a single dose of 1 mg/kg or 2 mg/kg AmBisome (besides
standard anti-bacterial prophylaxis) and a PK-curve will be drawn. These PK-values can then
be compared to the pharmacokinetics of a normal-weight group.